On Demand Webinars
Maximizing value across drug development: Embracing a new CDMO and CRO partnership approach
Pharma and biotech companies are facing increased competition and rising costs, alongside the ongoing pressure to deliver innovative therapies faster than ever.
Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply
Tech transfers for biological products, whether they occur from a pharma company, another CMO, or a different site within the same organization, are complex and challenging processes.
Waters Bioprocess Walk-Up Solutions
Learn how to improve process understanding and robustness, reduce costs and automate routine product quality and cell culture media analyses with a streamlined interface for sample preparation and LC-MS analytics. Real-time data acquisition and processing for informed decision-making.
Mastering analytical methods for fail-safe PPQ
After investing significant financial and temporal resources in the development of a new biologic molecule, companies cannot afford any setbacks in the final stages.
Pitfalls of PPQ: top risks and how to mitigate them to ensure successful commercialization
You’re almost at the finish line and you need to prove your biologic therapy's production process is robust and consistently meets purity, quality, and potency standards.
Late-phase biologics development: Embracing risk for competitive advantage
Risk is omnipresent in biologics development, particularly in late-phase manufacturing. Fears of a therapeutic candidate not meeting efficacy goals despite early positive results, alongside safety, quality, and scale-up concerns, loom large.
Innovative AI-Driven Solutions to Address the Growing Complexity of APIs
The complexity of small molecule active pharmaceutical ingredients (APIs) is rising, bringing longer syntheses that challenge innovators' timely readiness for the Clinic.
Utilizing Live Cell Imaging for Better Lead Selection of Biologics and Bioconjugates
Abzena is a Contract Design and Manufacturing Organisation (CDMO) focused on the development of complex biologics, including antibody-drug conjugates (ADCs) and bispecific antibodies.
Breaking Boundaries in Targeted Protein Degradation
Targeted protein degradation is redefining what’s possible in modern drug discovery. By harnessing the cell’s own machinery to eliminate disease-causing proteins, degraders and molecular glues are moving science beyond traditional inhibition—and into a new era of precision and control.
Modern Requirements for Laboratory Balances: A Global Pharmacopoeial Perspective
In recent years, the regulatory requirements for balances used in pharmaceutical analysis have undergone significant updates across major pharmacopoeias — including the USP (United States Pharmacopeia, latest version 07/2025), Ph. Eur. (European Pharmacopoeia, 07/2021, currently under revision), JP (Japanese Pharmacopoeia, 06/2024), and ChP (Chinese Pharmacopoeia, 03/2025).
